Management of patients with intermediate stage hepatocellular carcinoma
Hepatocellular carcinoma (HCC) causes a significant health burden globally and its impact is expected to increase in the coming years. Intermediate stage HCC, as defined by the Barcelona Clinic Liver Cancer (BCLC) system stage B, represents up to 30% of patients at diagnosis and encompasses a broad...
Main Authors: | David Prince, Ken Liu, Weiqi Xu, Minjiang Chen, Jin-Yu Sun, Xiao-Jie Lu, Jiansong Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920970840 |
Similar Items
-
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
by: Weiqi Xu, et al.
Published: (2019-07-01) -
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
by: Takuji Torimura, et al.
Published: (2021-04-01) -
Intermediate stage hepatocellular carcinoma: a summary review
by: Elshaarawy O, et al.
Published: (2019-07-01) -
Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
by: Shuling Chen, et al.
Published: (2019-04-01) -
Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma
by: Furong Liu, et al.
Published: (2019-01-01)